Interim results from a phase 2 trial of tazbentetol for treatment of schizophrenia showed trends of improving positive and negative symptoms in patients via synaptic regeneration.1 The safety profile was overall favorable, and biomarker signals indicated improvements in cortical abnormalities associated with schizophrenia, according to interim analysis presented at the Schizophrenia International Research Society 2026 Annual Congress.